Constant Therapy Announces Publication of Study


LEXINGTON, Mass., July 20, 2022 (GLOBE NEWSWIRE) — Health Constant Therapy, a digital brain health therapy company, today announced the publication of a dosing study in the Journal of Medical Internet Research titled “Dosage Frequency Effects on Treatment Outcomes After Self-managed Digital Therapy: Retrospective Cohort Study “. The study, conducted by a Boston University research team led by Dr. Swathi Kiran, analyzed data from Constant Therapy’s mobile speech, language and cognitive therapy program. The results determined the optimal dosing frequency for self-directed digital cognitive and speech therapy and demonstrated that increased dosing frequency is associated with better treatment outcomes for people with speech, language and/or cognitive disorders. post stroke.

Researchers analyzed anonymized data from 2,249 post-stroke survivors who used Constant therapy between 2016 and 2019. The data included therapy tasks covering 13 different domains of speech, language and cognitive skills. For each patient, the weekly treatment dosage was calculated based on the median number of days per week (1, 2, 3, 4, or 5+) of Constant Therapy use during the 10-week treatment period. Linear mixed-effects models (LMM) were run to examine changes in performance over time as a function of dosage group, with post-hoc comparisons of slopes to assess the performance gain associated with each day of additional practice. Significantly, research showed that patients who practiced more frequently achieved incremental improvements accumulating with each additional day of practice in the majority of skill areas, with four days of practice per week being the optimal dose.

“Constant Therapy has the world’s largest rehabilitation database for speech and cognition disorders in patients with different diagnoses and demographics and recently surpassed 200 million exercises performed by Constant Therapy users. . We are excited to partner with Boston University and other leading research institutes to use this data to advance brain science and accelerate real-world evidence to uncover new clinical insights,” said Veera Anantha, CEO and co-founder of Constant Therapy. “These study results demonstrate the benefits of providing digital therapy to patients at home so they can get the optimal dose of therapy to regain their cognitive abilities.”

This study is significant in several respects:

  • Due to barriers such as provider shortages, coverage caps, geographic isolation, lack of transportation, and other challenges, post-stroke patients are currently not receiving the optimal intensity of speech therapy and cognitive.1 Therefore, many providers recommend self-managed digital health technology like Constant Therapy to bridge the gap.
  • This study was conducted with anonymized data from 2,249 Constant Therapy users after stroke. This is a particularly important data set for a rehabilitation study, as many studies in the field are typically single-participant case studies or may include fewer than 50 participants.2

“Access to this very large real-world dataset from Constant Therapy illustrates real-world patient usage patterns outside of a research setting and underscores the real-world validity of the study findings, making thus the results more readily applicable to clinicians’ recommendations for therapy in clinical practice. This study represents an important step towards the development of optimal dose recommendations for mobile self-managed speech, language, and cognitive therapy,” notes Dr. Swathi Kiran, lead author, and the James and Cecilia Tse Ying Professor of Neurorehabilitation at Sargent College of Health and Rehabilitation Sciences, Director of the Aphasia Research Laboratory at Boston University Dr. Kiran is also the co-founder of Constant Therapy.

About Constant Therapy Health:
Constant Therapy Health is a next-generation digital therapy company whose technology is clinically proven to improve the effectiveness of cognitive, speech and language therapy, as well as increase access and reduce the cost of therapy. Constant Therapy, an award-winning mobile program, uses patented artificial intelligence technology to deliver personalized exercises that rebuild cognitive and speech function for people recovering from stroke or traumatic brain injury (TBI). ) or who live with aphasia, dementia and other neurological disorders. Built by a team of top neuroscientists at Boston University, Constant Therapy is used by tens of thousands of patients and clinicians, helping to create the world’s largest brain rehabilitation database and providing information that can improve the effectiveness and efficiency of cerebral rehabilitation. Visit our website and follow us on LinkedIn to learn more or to partner with us.

  1. .Cavanaugh, R., Kravetz, C., Jarold, L., Quique, Y., Turner, R. & Evans, WS (2021, September 23). Is there a balance gap between research and practice in aphasia rehabilitation? Am J Speech Lang Pathol, 30(5), 2115-2129.
  2. Harvey, SR, Carragher, M., Dickey, MW, Pierce, JE and Rose, ML (2021, December). Treatment dose in post-stroke aphasia: a systematic scoping review. Neuropsychol Rehabilitation, 31(10), 1629-1660.

Media Contact:
Helen Shik
Shik Communications
[email protected]

Original post:
Cordella C, Munsell M, Godlove J, Anantha V, Advani M, Kiran S. Dosing frequency
Effects on Treatment Outcomes Following Self-Managed Digital Therapy: A Retrospective
Cohort study. J Med Internet Res. 2022;24(7):e36135




Comments are closed.